5 Key Takeaways
-
1
Atsena Therapeutics presented 18-month results from the LIGHTHOUSE trial at the 2026 American Academy of Optometry meeting.
-
2
ATSN-201, an investigational gene therapy for XLRS, showed sustained structural and functional changes in treated patients.
-
3
Foveal schisis closure was maintained in 7 of 9 treated eyes, while untreated eyes showed no closure.
-
4
Six treated eyes improved by at least 7 dB on microperimetry, compared to none in the untreated group.
-
5
No serious adverse events or treatment discontinuations were reported, and enrollment for the pivotal cohort continues.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.